EGFR and non-small cell lung carcinoma: We conducted the first prospective phase II study on gefitinib induction followed by chemoradiotherapy in 20 patients with EGFR-mutant LA-NSCLC [4,5]. The protocol therapy yielded promising results with a two-year survival rate of 90% (18/20 patients; 90% CI: 71.4-96.8) and an overall response rate (ORR) of 85% (17/20 patients).